Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
Open Access
- 14 May 2022
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (11) , 2265-2272
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionGastroenterology, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionNew England Journal of Medicine, 2015
- Predictive factors associated with hepatitis C antiviral therapy responseWorld Journal of Hepatology, 2015
- Natural history of hepatitis CJournal of Hepatology, 2014
- Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinomaInternational Journal of Cancer, 2014
- Hepatitis C genotype 6: A concise review and response-guided therapy proposalWorld Journal of Hepatology, 2013
- Management of adverse events during the treatment of chronic hepatitis C infectionClinical Liver Disease, 2012
- Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening ParticipantsJournal of the Formosan Medical Association, 2007
- Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implicationsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in TaiwanJournal of Medical Virology, 2001